2010
Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3
Fowke JH, Matthews CE, Yu H, Cai Q, Cohen S, Buchowski MS, Zheng W, Blot WJ. Racial differences in the association between body mass index and serum IGF1, IGF2, and IGFBP3. Endocrine Related Cancer 2010, 17: 51-60. PMID: 19786462, PMCID: PMC2814999, DOI: 10.1677/erc-09-0023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge of OnsetAgedBlack or African AmericanBody Mass IndexBreast NeoplasmsCross-Sectional StudiesFemaleFollow-Up StudiesGenetic Predisposition to DiseaseHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor Binding ProteinsInsulin-Like Growth Factor IInsulin-Like Growth Factor IIMiddle AgedPostmenopausePremenopauseProspective StudiesSoutheastern United StatesWhite PeopleYoung AdultConceptsBody mass indexAge 21 yearsBreast cancer riskIGF1 levelsRace/ethnicityIGFBP3 levelsMass indexWhite womenAA womenCancer riskRacial differencesPremenopausal breast cancer riskAfrican American race/ethnicityLower body mass indexEffect of obesityHigher IGF1 levelsCross-sectional analysisFree IGF1Serum IGF1IGF levelsBMI rangeAge 40Wide BMI rangeProtein 3Women
2004
Insulin‐like growth factor‐I gene polymorphism and breast cancer risk in Chinese women
Wen W, Gao Y, Shu X, Yu H, Cai Q, Smith J, Zheng W. Insulin‐like growth factor‐I gene polymorphism and breast cancer risk in Chinese women. International Journal Of Cancer 2004, 113: 307-311. PMID: 15386404, DOI: 10.1002/ijc.20571.Peer-Reviewed Original ResearchConceptsBreast cancer riskBreast cancerPremenopausal womenCancer riskPopulation-based case-control studyAge frequency-matched controlsChinese womenIncident breast cancer casesPlasma IGF-I levelsInsulin-like growth factorIGF-I levelsFrequency-matched controlsCase-control studyBreast cancer casesAssociation of IGFDose-response mannerMeta-analysis resultsBreast cancer susceptibilityIGF-I geneSignificant genetic factorInsulin-like growth factor-I gene polymorphismPlasma IGFCancer casesGeneral populationGene polymorphismsIGF‐I and breast cancer: A meta‐analysis
Shi R, Yu H, McLarty J, Glass J. IGF‐I and breast cancer: A meta‐analysis. International Journal Of Cancer 2004, 111: 418-423. PMID: 15221971, DOI: 10.1002/ijc.20233.Peer-Reviewed Original ResearchConceptsHedges's standardized mean differenceIGFBP-3 levelsLevels of IGFIGF-binding proteinsBreast cancer riskStandardized mean differencePremenopausal womenBreast cancerIGFBP-3Cancer riskBreast cancer patientsEffects of IGFPostmenopausal womenPostmenopausal groupPremenopausal groupHigher IGFCancer patientsClinical studiesEpidemiologic studiesParacrine mechanismsIGFOverall associationMean differenceCancerWomenReports: Insulin-Like Growth Factor-I, Soy Protein Intake, and Breast Cancer Risk
Sanderson M, Shu X, Yu H, Dai Q, Malin A, Gao Y, Zheng W. Reports: Insulin-Like Growth Factor-I, Soy Protein Intake, and Breast Cancer Risk. Nutrition And Cancer 2004, 50: 8-15. PMID: 15572292, DOI: 10.1207/s15327914nc5001_2.Peer-Reviewed Original ResearchConceptsIGF-I levelsShanghai Breast Cancer StudyIGFBP-3 levelsSoy protein intakeBreast cancer riskCancer riskProtein intakeBreast cancerInsulin-like growth factor-binding protein-3 levelsPopulation-based case-control studyIncident breast cancer casesPremenopausal breast cancer riskPopulation-based cancer registriesBreast cancer cell growthInsulin-like growth factorPremenopausal breast cancerProtein-3 levelsEffects of IGFCase-control studyBreast cancer casesInsulin-like growthCancer cell growthBreast Cancer StudyPostmenopausal womenCancer Registry
2002
Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors.
Chang S, Wu X, Yu H, Spitz M. Plasma concentrations of insulin-like growth factors among healthy adult men and postmenopausal women: associations with body composition, lifestyle, and reproductive factors. Cancer Epidemiology Biomarkers & Prevention 2002, 11: 758-66. PMID: 12163330.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorIGF BP-3 levelsBody mass indexBP-3 levelsIGF BP-3IGF-II levelsHormone replacement therapyIGF-I levelsLow physical activityIGF levelsIGF-IIPhysical activityPostmenopausal womenHRT useCaloric intakeReproductive factorsLower IGF-II levelsTraditional cancer risk factorsLow IGF-I levelsPlasma insulin-like growth factorHigher body mass indexGrowth factorIGF-BP levelsPlasma IGF-IIRecent HRT use
2001
Free insulin‐like growth factor‐I and breast cancer risk
Li B, Khosravi M, Berkel H, Diamandi A, Dayton M, Smith M, Yu H. Free insulin‐like growth factor‐I and breast cancer risk. International Journal Of Cancer 2001, 91: 736-739. PMID: 11267989, DOI: 10.1002/1097-0215(200002)9999:9999<::aid-ijc1111>3.0.co;2-#.Peer-Reviewed Original ResearchConceptsIGF-I receptorInsulin-like growth factorFree IGFIGFBP-3Action of IGFBreast cancer patientsTotal IGFBreast cancer riskBreast cancerIGF-IICancer patientsPlasma levelsCancer riskFree insulin-like growth factorRace-matched healthy controlsFree IGF-I levelsConditional logistic regression analysisGrowth factorIGF-I levelsIGF binding proteinBinding of IGFHigher plasma levelsLogistic regression analysisHigher plasma IGFAnti-apoptotic effects
1999
Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer
Foekens J, Diamandis E, Yu H, Look M, Gelder M, Putten W, Klijn J. Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. British Journal Of Cancer 1999, 79: 888-894. PMID: 10070886, PMCID: PMC2362687, DOI: 10.1038/sj.bjc.6690142.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, HormonalBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansLymphatic MetastasisMiddle AgedNeoplasm StagingPostmenopausePredictive Value of TestsPremenopauseProstate-Specific AntigenReceptors, EstrogenReceptors, ProgesteroneRetrospective StudiesSurvival AnalysisTamoxifenTime FactorsConceptsLevels of PSAProstate-specific antigenPrimary breast cancerRecurrent breast cancerBreast tumor cytosolsBreast cancerRecurrent diseaseEnzyme-linked immunosorbent assayTamoxifen therapyPoor responseTumor cytosolsAge/menopausal statusFirst-line tamoxifen therapyHormone receptor-negative tumorsSteroid hormone receptor statusDisease-free intervalSite of relapseCox multivariate analysisHormone receptor statusReceptor-negative tumorsClassical prognostic factorsPost-menopausal patientsRate of relapseBreast cancer patientsStart of treatment